Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003).
Saved in:
| Title: | Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003). |
|---|---|
| Authors: | Strati P; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Agajanian R; The Oncology Institute of Hope and Innovation, Downey, California, USA., Lossos IS; Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, Miami, Florida, USA., Coleman M; Clinical Research Alliance/Weill Cornell Medicine, New York, New York, USA., Kridel R; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Wood A; AstraZeneca, Cambridge, UK., Lesley R; AstraZeneca, South San Francisco, California, USA., Wun CC; AstraZeneca, South San Francisco, California, USA., Stephens DM; University of North Carolina Lineberger Cancer Center, Chapel Hill, North Carolina, USA. |
| Source: | British journal of haematology [Br J Haematol] 2025 Mar; Vol. 206 (3), pp. 887-898. Date of Electronic Publication: 2024 Dec 12. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Multicenter Study |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1365-2141 |
|---|---|
| DOI: | 10.1111/bjh.19951 |
